news

Biocelect Pty Ltd today announced the Australian launch of Jext, a new adrenaline autoinjector now listed on the Pharmaceutical Benefits Scheme (PBS) and available nationally, supporting subsidised access for eligible patients for the emergency treatment of anaphylaxis (1-2).    The introduction of Jext adds an additional PBS listed adrenaline autoinjector option to the established anaphylaxis treatment landscape in Australia, providing healthcare professionals and pharmacis

VAXCHORA® is indicated for active immunisation against disease caused by Vibrio cholerae serogroup O1 in adults and children aged 2 years...

As of February 17 2023, Biocelect Pty Ltd is proud to have added IMOJEV (Japanese encephalitis vaccine, live attenuated) to our portfolio...

Biocelect is proud to partner with NSW Health and NOVAVAX INC on clinical trials and making new vaccines available for all Australians